How cost pressures under Obamacare can be a boon to the biotech industry

Could the increasingly cost-conscious healthcare environment under Obamacare acually be good for local biotech firms? The recent launches of drugs with high up-front costs have revived the longstanding debate over how much new medicines ought to cost...